Regulatory News
Wednesday, September 7, 2016
BRIEF-Merck says FDA grants breakthrough therapy designation to Keytruda
* FDA accepts supplemental biologics license application,
assigns priority review and grants breakthrough therapy
designation to Merck's Keytruda (pembrolizumab) for first-line
treatment of patients...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment